dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Mateo, Lidia |
dc.contributor.author | Duran-Frigola, Miquel |
dc.contributor.author | Palafox Sánchez, Marta |
dc.contributor.author | Scaltriti, Maurizio |
dc.contributor.author | Razavi, Pedram |
dc.contributor.author | Arribas López, Joaquin Vicente |
dc.contributor.author | Serra Elizalde, Violeta |
dc.contributor.author | Gris Oliver, Albert |
dc.contributor.author | Bellet Ezquerra, Meritxell |
dc.date.accessioned | 2021-09-03T10:37:24Z |
dc.date.available | 2021-09-03T10:37:24Z |
dc.date.issued | 2020-09-09 |
dc.identifier.citation | Mateo L, Duran-Frigola M, Gris-Oliver A, Palafox M, Scaltriti M, Razavi P, et al. Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Med. 2020 Sep 9;12:78. |
dc.identifier.issn | 1756-994X |
dc.identifier.uri | https://hdl.handle.net/11351/6265 |
dc.description | Biomarcadors de resposta a fàrmacs; Xarxes de co-ocurrència de conductors; Oncologia de precisió |
dc.description.sponsorship | L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the Generalitat de Catalunya (VEIS 001-P-001). V.S. is a recipient of a Miguel Servet grant from ISCIII (CPII19/00033) and receives funds from AGAUR (2017 SGR 540). The PDX program is supported by a GHD-Pink (FERO foundation) grant to V.S., A.G.-O. and M.P. received a FI-AGAUR and a Juan de la Cierva (MJCI-2015-25412) fellowship, respectively. M.S., P.R., and S.C. acknowledge the support of the NIH grants P30 CA008748, RO1CA190642, and the Breast Cancer Research Foundation. Additionally, P.R. receives funds from the Breast Cancer Alliance. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Genome Medicine;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Medicina personalitzada |
dc.subject.mesh | Precision Medicine |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /therapy |
dc.title | Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s13073-020-00774-x |
dc.subject.decs | medicina de precisión |
dc.subject.decs | neoplasias |
dc.subject.decs | /terapia |
dc.relation.publishversion | https://doi.org/10.1186/s13073-020-00774-x |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Mateo L, Duran-Frigola M] Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain. [Gris-Oliver A, Palafox M] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Scaltriti M] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA. Department of Pathology, MSKC C, New York, NY 10065, USA. [Razavi P] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA. Breast Medicine Service, Department of Medicine, MSKCC and Weill-Cornell Medical College, New York, NY 10065, USA. [Arribas J] Growth Factors Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. CIBERONC, Barcelona, Spain. [Bellet M] Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Serra V] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. CIBERONC, Barcelona, Spain |
dc.identifier.pmid | 32907621 |
dc.identifier.wos | 000571544000001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/BIO2016-77038-R |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/614944 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/CPII19%2F00033 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR540 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |